Last reviewed · How we verify
CDK Inhibitor AT7519
At a glance
| Generic name | CDK Inhibitor AT7519 |
|---|---|
| Also known as | AT-7519, AT7519, AT7519M, CDK inhibitor AT7519M, Cyclin-Dependent Kinase Inhibitor AT7519M |
| Sponsor | National Cancer Institute (NCI) |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (PHASE1)
- AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |